Hims & Hers Health (NYSE:HIMS) Price Target Raised to $25.00 at Leerink Partners

Hims & Hers Health (NYSE:HIMS) had its price objective hoisted by Leerink Partners from $17.50 to $25.00 in a research report released on Monday,Benzinga reports. Leerink Partners currently has a market perform rating on the stock.

Several other brokerages have also weighed in on HIMS. BTIG Research lowered Hims & Hers Health from a “buy” rating to a “neutral” rating in a report on Tuesday, February 24th. Evercore set a $24.00 price target on Hims & Hers Health in a research report on Tuesday, February 24th. Weiss Ratings reiterated a “hold (c)” rating on shares of Hims & Hers Health in a research note on Monday, December 29th. Zacks Research raised Hims & Hers Health from a “strong sell” rating to a “hold” rating in a report on Wednesday, February 25th. Finally, Barclays boosted their price objective on Hims & Hers Health from $25.00 to $29.00 and gave the company an “overweight” rating in a research note on Wednesday, March 11th. Three equities research analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $31.29.

Hims & Hers Health Stock Up 0.9%

HIMS opened at $24.99 on Monday. Hims & Hers Health has a twelve month low of $13.74 and a twelve month high of $70.43. The company’s 50-day moving average price is $23.64 and its two-hundred day moving average price is $37.20. The stock has a market cap of $5.70 billion, a price-to-earnings ratio of 49.00, a PEG ratio of 2.34 and a beta of 2.56. The company has a quick ratio of 1.70, a current ratio of 1.90 and a debt-to-equity ratio of 1.80.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, February 23rd. The company reported $0.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.02 by $0.06. The company had revenue of $617.82 million during the quarter, compared to analyst estimates of $619.48 million. Hims & Hers Health had a net margin of 5.47% and a return on equity of 22.48%. Hims & Hers Health’s quarterly revenue was up 28.4% compared to the same quarter last year. During the same quarter last year, the business posted $0.11 EPS. As a group, equities analysts expect that Hims & Hers Health will post 0.29 earnings per share for the current year.

Hims & Hers Health announced that its Board of Directors has initiated a share repurchase plan on Monday, November 17th that allows the company to buyback $250.00 million in outstanding shares. This buyback authorization allows the company to reacquire up to 3% of its shares through open market purchases. Shares buyback plans are often a sign that the company’s board of directors believes its stock is undervalued.

Insider Activity

In related news, CFO Oluyemi Okupe sold 9,067 shares of the business’s stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $30.34, for a total transaction of $275,092.78. Following the sale, the chief financial officer directly owned 91,617 shares in the company, valued at approximately $2,779,659.78. The trade was a 9.01% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Patrick Harrison Carroll sold 10,021 shares of the business’s stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total value of $367,870.91. Following the sale, the insider owned 169,940 shares in the company, valued at approximately $6,238,497.40. The trade was a 5.57% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 80,463 shares of company stock valued at $2,846,696. 17.71% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Quent Capital LLC bought a new stake in shares of Hims & Hers Health during the third quarter valued at about $28,000. Binnacle Investments Inc bought a new position in shares of Hims & Hers Health in the third quarter valued at approximately $28,000. Virtus Advisers LLC bought a new position in shares of Hims & Hers Health in the second quarter valued at approximately $26,000. Hilltop National Bank purchased a new position in Hims & Hers Health during the third quarter valued at approximately $35,000. Finally, Skandinaviska Enskilda Banken AB publ grew its stake in Hims & Hers Health by 408.2% during the second quarter. Skandinaviska Enskilda Banken AB publ now owns 747 shares of the company’s stock valued at $37,000 after acquiring an additional 600 shares in the last quarter. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.